Olga Mityaeva

Dr. Olga Mityaeva

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
ABArtem Blagodatski
Artem Blagodatski
KTKseniya Trutneva
Kseniya Trutneva
OGOlga Glazova
Olga Glazova
OMOlga Mityaeva
Olga Mityaeva
LSLiudmila Shevkova
Liudmila Shevkova
PVPavel Volchkov
Pavel Volchkov
Avian influenza is one of the largest known threats to domestic poultry. Influenza outbreaks on poultry farms typically lead to the complete slaughter of the entire domestic bird population, causing severe economic losses worldwide. Moreover, there are highly pathogenic avian influenza (HPAI) strains that are able to infect the swine or human population in addition to their primary avian host and, as such, have the potential of being a global zoonotic and pandemic threat. Migratory birds, especially waterfowl, are a natural reservoir of the avian influenza virus; they carry and exchange different virus strains along their migration routes, leading to antigenic drift and antigenic shift, which results in the emergence of novel HPAI viruses. This requires monitoring over time and in different locations to allow for the upkeep of relevant knowledge on avian influenza virus evolution and the prevention of novel epizootic and epidemic outbreaks. In this review, we assess the role of migratory birds in the spread and introduction of influenza strains on a global level, based on recent data. Our analysis sheds light on the details of viral dissemination linked to avian migration, the viral exchange between migratory waterfowl and domestic poultry, virus ecology in general, and viral evolution as a process tightly linked to bird migration. We also provide insight into methods used to detect and quantify avian influenza in the wild. This review may be beneficial for the influenza research community and may pave the way to novel strategies of avian influenza and HPAI zoonosis outbreak monitoring and prevention.

27 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
VAValentin Artemyev
Valentin Artemyev
AGAnna Gubaeva
Anna Gubaeva
APAnastasiia Iurevna Paremskaia
Anastasiia Iurevna Paremskaia
ADAmina Dzhioeva
Amina Dzhioeva
ADAndrei A Deviatkin
Andrei A Deviatkin
PVPavel Volchkov
Pavel Volchkov
Gene therapy is a promising approach to the treatment of various inherited diseases, but its development is complicated by a number of limitations of the natural promoters used. The currently used strong ubiquitous natural promoters do not allow for the specificity of expression, while natural tissue-specific promoters have lowactivity. These limitations of natural promoters can be addressed by creating new synthetic promoters that achieve high levels of tissue-specific target gene expression. This review discusses recent advances in the development of synthetic promoters that provide a more precise regulation of gene expression. Approaches to the design of synthetic promoters are reviewed, including manual design and bioinformatic methods using machine learning. Examples of successful applications of synthetic promoters in the therapy of hereditary diseases and cancer are presented, as well as prospects for their clinical use.

1 April 2023 in Heliyon
Verified
Journal Article
Open access
WAWalaa Asaad
Walaa Asaad
PVPolina Volos
Polina Volos
DMDenis Maksimov
Denis Maksimov
EKElena Khavina
Elena Khavina
ADAndrei Deviatkin
Andrei Deviatkin
PVPavel Volchkov
Pavel Volchkov
The adeno-associated virus (AAV) is one of the most potent vectors in gene therapy. The experimental profile of this vector shows its efficiency and accepted safety, which explains its increased usage by scientists for the research and treatment of a wide range of diseases. These studies require using functional, pure, and high titers of vector particles. In fact, the current knowledge of AAV structure and genome helps improve the scalable production of AAV vectors. In this review, we summarize the latest studies on the optimization of scalable AAV production through modifying the AAV genome or biological processes inside the cell.

Verified
Journal Article
Open access
PDF file
ASAnastasiia Soroka
Anastasiia Soroka
SFSofya G. Feoktistova
Sofya G. Feoktistova
OMOlga Mityaeva
Olga Mityaeva
PVPavel Volchkov
Pavel Volchkov
In contrast to the standard enzyme-replacement therapy, administered from once per 7–14 days to 2–3 times a week in patients with severe hemophilia B, as a result of a single injection, gene therapy can restore F9 gene expression and maintain it for a prolonged time. In clinical research, the approach of delivering a functional copy of a gene using adeno-associated viral (AAV) vectors is widely used. The scientific community is actively researching possible modifications to improve delivery efficiency and expression. In preclinical studies, the possibility of genome editing using CRISPR/Cas9 technology for the treatment of hemophilia B is also being actively studied.

20 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ADAndrei A Deviatkin
Andrei A Deviatkin
RSRuslan Simonov
Ruslan Simonov
KTKseniya Trutneva
Kseniya Trutneva
AMAnna Maznina
Anna Maznina
ASAnastasiia Soroka
Anastasiia Soroka
PVPavel Volchkov
Pavel Volchkov
Recently, the mRNA platform has become the method of choice in vaccine development to find new ways to fight infectious diseases. However, this approach has shortcomings, namely that mRNA vaccines require special storage conditions, which makes them less accessible. This instability is due to the fact that the five-prime and three-prime ends of the mRNA are a substrate for the ubiquitous exoribonucleases. To address the problem, circular mRNAs have been proposed for transgene delivery as they lack these ends. Notably, circular RNAs do not have a capped five-prime end, which makes it impossible to initiate translation canonically. In this review, we summarize the current knowledge on cap-independent translation initiation methods and discuss which approaches might be most effective in developing vaccines and other biotechnological products based on circular mRNAs.

1 March 2022 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AKAlexey A. Komissarov
Alexey A. Komissarov
ISInna Shuliakova
Inna Shuliakova
GEGrigory A Efimov
Grigory A Efimov
DLDenis Y. Logunov
Denis Y. Logunov
OMOlga Mityaeva
Olga Mityaeva
EVElena Vasilieva
Elena Vasilieva
Despite measures taken world-wide, the coronavirus disease 2019 (COVID-19) pandemic continues. Because efficient antiviral drugs are not yet widely available, vaccination is the best option to control the infection rate. Although this option is obvious in the case of COVID-19–naive individuals, it is still unclear when individuals who have recovered from a previous SARS-CoV-2 infection should be vaccinated and whether the vaccination raises immune responses against the coronavirus and its novel variants. In this study, we collected peripheral blood from 84 healthy human donors of different COVID-19 status who were vaccinated with the Sputnik Light vaccine and measured the dynamics of the Ab and T cell responses, as well as the virus-neutralizing activity (VNA) in serum, against two SARS-CoV-2 variants, B.1.1.1 and B.1.617.2. We showed that vaccination of individuals previously exposed to the virus considerably boosts the existing immune response. In these individuals, receptor-binding domain (RBD)–specific IgG titers and VNA in serum were already elevated on the 7th day after vaccination, whereas COVID-19–naive individuals developed the Ab response and VNA mainly 21 d postvaccination. Additionally, we found a strong correlation between RBD-specific IgG titers and VNA in serum, and according to these data vaccination may be recommended when the RBD-specific IgG titers drop to 142.7 binding Ab units/ml or below. In summary, the results of the study demonstrate that vaccination is beneficial for both COVID-19–naive and recovered individuals, especially since it raises serum VNA against the B.1.617.2 variant, one of the five SARS-CoV-2 variants of concern.